News
DGX
135.42
-1.55%
-2.13
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Dow Jones · 11h ago
Quest Diagnostics Price Target Raised to $144.00/Share From $138.00 by Barclays
Dow Jones · 11h ago
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144
Benzinga · 11h ago
Labcorp beats quarterly estimates on strong testing demand
Labcorp beats quarterly estimates on strong testing demand. Growing demand for specialty tests boosted sales at its diagnostics business. More people in the U.S. Are catching up on medical procedures and routine check-ups. The company reported first-quarter profit of $3.68 per share.
Reuters · 19h ago
QUEST DIAGNOSTICS INC <DGX.N>: BARCLAYS RAISES TARGET PRICE TO $144 FROM $138
Reuters · 19h ago
Quest Diagnostics Inc Quarterly Report for the Period Ended March 31, 2024
Press release · 1d ago
Peering Into Quest Diagnostics's Recent Short Interest
Quest Diagnostics's short percent of float has fallen 16.83% since its last report. The company has 2.55 million shares sold short, which is 2.62% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 1d ago
Quest Diagnostics Is Maintained at Neutral by Citigroup
Dow Jones · 1d ago
Quest Diagnostics Price Target Raised to $145.00/Share From $135.00 by Citigroup
Dow Jones · 1d ago
Citigroup Maintains Neutral on Quest Diagnostics, Raises Price Target to $145
Benzinga · 1d ago
Quest Diagnostics Is Maintained at Neutral by UBS
Dow Jones · 1d ago
UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $146
Benzinga · 1d ago
QUEST DIAGNOSTICS INC <DGX.N>: JEFFERIES RAISES TARGET PRICE TO $160 FROM $155
Reuters · 1d ago
QUEST DIAGNOSTICS INC <DGX.N>: UBS RAISES TARGET PRICE TO $146 FROM $139
Reuters · 1d ago
Quest Diagnostics Price Target Raised to $150.00/Share From $145.00 by Truist Securities
Dow Jones · 1d ago
Quest Diagnostics Is Maintained at Hold by Truist Securities
Dow Jones · 1d ago
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $150
Benzinga · 1d ago
QUEST DIAGNOSTICS <DGX.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $136 FROM $125
Reuters · 1d ago
Quest Diagnostics Is Maintained at Buy by Mizuho
Dow Jones · 1d ago
Quest Diagnostics Price Target Raised to $155.00/Share From $150.00 by Mizuho
Dow Jones · 1d ago
More
Webull provides a variety of real-time DGX stock news. You can receive the latest news about Quest Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.